Clinical Analysis Of 43 Light Chain Multiple Myeloma Patients

Objective:The aim of this study was to summarize clinical and laboratory features, treatment response of light chain multiple myeloma(LCMM), so as to strengthen understanding of LCMM, provide exact basis for diagnosis and treatment, make patients can be diagnosed and treated timely.Methods:This retrospective study enrolled 43 newly diagnosed inpatients of LCMM in the First Affiliated Hospital of Guangxi Medical University from June 2009 to December 2015. The sex, age, clinical manifestations, serum β2-MG, organ damage and treatment response of LCMM were analyzed by single factor analysis.Results:①The median age of 43 LCMM patients was 57 years old, and the male to female ratio was 1.87:1. The proportion of patients at DS stage Ⅲ was 90.3% at diagnosis. ②The incidence of bone lesions, anemia, renal insufficiency and hypercalcemia was 89.7%,72.1%,46.5% and 18.6%, respectively in 43 LCMM patients. ③Renal failure and hypercalcemia crisis accounted for 16.3% and 7.0%, respectively in 43 LCMM patients. Ⅱ degree of bone lesions accounted for 62.9% in 35 LCMM patients with bone lesions,and moderate and severe anemia accounted for 80.7% in 31 LCMM patients with anemia. ④18 LCMM patients received at least 4 cycles chemotherapy, got the CR rate of 27.8% and ORR of 55.6%.Conclusions:①LCMM mostly occur in elder people and males, and most patients are stage III in the Durie-Salmon staging system at diagnosis.②LCMM patients suffer from serious organ damages.